Effectiveness of Isoniazid Preventive Therapy to Reduce Tuberculosis Incidence in the Context of Antiretroviral Therapy

J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):e14-e17. doi: 10.1097/QAI.0000000000002339.

Authors

Jody M Boffa^{1

2}, Dina A Fisher³, Maria J Mayan⁴, Reginald S Sauve³, Tyler S Williamson³

Affiliations

¹ Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada.
² Centre for Rural Health, School of Nursing and Public Health, University of KwaZulu-Natal, South Africa.
³ Department of Community Health Medicine, University of Calgary, Canada.
⁴ Community University Partnerships, Faculty of Extension, University of Alberta, Canada.

PMID: 32118612
DOI: 10.1097/QAI.0000000000002339

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Anti-Retroviral Agents / therapeutic use
CD4 Lymphocyte Count
Female
HIV Infections / complications
HIV Infections / drug therapy*
HIV Infections / epidemiology
Humans
Incidence
Isoniazid / therapeutic use*
Male
Middle Aged
South Africa / epidemiology
Tuberculosis / drug therapy*
Tuberculosis / epidemiology
Tuberculosis / prevention & control*
Young Adult

Substances

Anti-Retroviral Agents
Isoniazid